Form 6-K GENETIC TECHNOLOGIES For: Jan 29

�

FORM�6-K

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

�

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

�

dated January�29, 2015

�

Commission File Number 0-51504

�

GENETIC TECHNOLOGIES LIMITED

(Exact Name as Specified in its Charter)

�

N/A

(Translation of Registrant�s Name)

�

60-66 Hanover Street

Fitzroy

Victoria 3065 Australia

(Address of principal executive offices)

�

Indicate by check mark whether the registrant files or will file annual reports under cover of Form�20-F or Form�40-F.

�

Form�20-F x����Form�40-F o

�

Indicate by check mark if the registrant is submitting the Form�6-K in paper as permitted by Regulation S-T Rule�101(b)(1):��o

�

Indicate by check mark if the registrant is submitting the Form�6-K in paper as permitted by Regulation S-T Rule�101(b)(7):��o

�

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule�12g3-2(b)�under the Securities Exchange Act of 1934.

�

Yes��o����No x

�

If �Yes� is marked, indicate below the file number assigned to the registrant in connection with Rule�12g3-2(b):� Not applicable.

�

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused the Report to be signed on its behalf by the undersigned, thereunto duly authorized.

�

Date:� January�29, 2015

�

�	GENETIC TECHNOLOGIES LIMITED
�	�	�
�	�	�
�	By:	/s/ Bronwyn Christie
�	�	Name:	Bronwyn Christie
�	�	Title:	Company Secretary

�

2

�

EXHIBIT�INDEX

�

Exhibit	�	Description�of�Exhibit
�	�	�
99.1	�	ASX Announcement, January�29, 2015
99.2	�	ASX Announcement, January 29, 2015

�

3

Exhibit 99.1

�

�

�

Exhibit�99.2

�

ASX ANNOUNCEMENT

29 January�2015

�

Up to 6 New Breast Centres to begin offering BREVAGenplus�

�

Melbourne, Australia, 29 January�2015: Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, �Company�) is pleased to report that up to 6 new breast diagnosis/treatment centres are expected to begin offering BREVAGenplus� to their at-risk patients in a systematic broad fashion in the January�to March�timeframe, with a growing number of additional new breast and imaging centre customers expected to follow later in calendar year 2015. As a result, the Company expects sales growth to accelerate in the second half 2015 and beyond.

�

Prior to the release of BREVAGenplus, the Company revised its sales strategy to focus on large comprehensive breast treatment and imaging centres, in concert with its ongoing approach to independent physician and women�s healthcare providers. This recent pivotal change of sales and marketing emphasis towards large breast centres, which are more complex entities with a longer sales cycle, but with higher potential, is expected to lead to significant acceleration in growth and less volatile test volumes than the Company has experienced to date.

�

In October�2014, the Company announced the US release of BREVAGenplus, an easy-to-use predictive risk test for the millions of women at risk of developing sporadic, or non-hereditary, breast cancer, representing a marked enhancement in accuracy and broader patient applicability, over the Company�s first generation BREVAGenTM�product. Results from BREVAGenplus provide physicians with valuable information to assist in developing a patient-specific Breast Cancer Risk Reduction and Screening Plan based on professional medical society guidelines, such as the American Cancer Society (ACS) (www.cancer.org) and The National Comprehensive Cancer Network (NCCN) (www.nccn.org).

�

FOR FURTHER INFORMATION PLEASE CONTACT

�

Mr.�Eutillio Buccilli	Candice Knoll (USA)
Chief Operating Officer�&	Blueprint Life Science Group
Chief Financial Officer	+1 (415) 375 3340, Ext. 105
Genetic Technologies Limited	�
+ 61 3 8412 7050	�

�

About Genetic Technologies Limited

�

Genetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women�s health. The Company�s lead product, BREVAGenplus�, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus� improves upon the predictive power of the first generation

�

�

BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus��expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.

�

The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus�, launched in October�2014, significantly expands the applicable market. The Company markets BREVAGenplus��to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).

�

For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

�

Safe Harbor Statement

�

Any statements in this press release that relate to the Company�s expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act.� The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees.� Since this information may involve risks and uncertainties and are subject to change at any time, the Company�s actual results may differ materially from expected results.� Additional risks associated with Genetic Technologies� business can be found in its periodic filings with the SEC.

�

Genetic Technologies Limited� Website: www.gtglabs.com � Email: [email protected]� ABN 17 009 212 328

Registered Office� 60-66 Hanover Street Fitzroy Victoria 3065 Australia � Postal Address P.O.�Box 115 Fitzroy Victoria 3065 Australia

Phone +61 3 8412 7000 � Fax +61 3 8412 7040

NY 244953710v1

�